In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 2, 2012, Pages 146-152

  Choi, Hee Young ^a   Lee, Ji Eun ^a,b   Lee, Ji Woong ^a   Park, Hyun Jun ^b   Jung, Jae Ho ^a,b  

^a Pusan National University Hospital   (South Korea)

^b Pusan National University Yangsan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; BIOLOGICAL MARKER; CCAAT ENHANCER BINDING PROTEIN ALPHA; LATANOPROST; LIPID; LIPOPROTEIN LIPASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TAFLUPROST; TRAVOPROST;

ADIPOCYTE; ADIPOGENESIS; ADULT; ARTICLE; BIOACCUMULATION; CELL DIFFERENTIATION; CELL METABOLISM; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EYELID; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; ORBIT; PATHOPHYSIOLOGY; PROADIPOCYTE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADIPOCYTES; ADIPOGENESIS; ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CLOPROSTENOL; DINOPROST; HUMANS; LIPOPROTEIN LIPASE; ORBIT; PPAR GAMMA; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC; YOUNG ADULT;

EID: 84859409270     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0160     Document Type: Article

References (31)

1. Tsuboi, K., Sugimoto, Y., and Ichikawa, A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat. 68-69:535-556, 2002. (Pubitemid 35247419)
2. Hata, A.N., and Breyer, R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103:147-166, 2004. (Pubitemid 39209041)
3. Ishida, N., Odani-Kawabata, N., Shimazaki, A., and Hara, H. Prostanoids in the therapy of glaucoma. Cardiovasc. Drug Rev. 24:1-10, 2006. (Pubitemid 46696782)
4. Hylton, C., and Robin, A.L. Update on prostaglandin analogs. Curr. Opin. Ophthalmol. 14:65-69, 2003. (Pubitemid 36584222)
5. Camras, C.B.; United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology 103:138-147, 1996. (Pubitemid 26046170)
6. Parrish, R.K., Palmberg, P., and Sheu, W.P.; XLT Study Group. A comparison of latanoprost, bimatoprost, and tra-voprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. 135:688-703, 2003. (Pubitemid 36457976)
7. Sagara, T., Gaton, D.D., Lindsey, J.D., et al. Topical prosta-glandin F2 treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol. 117:794-801, 1999. (Pubitemid 29265042)
8. Vogel, R., Strahlman, E., and Rittenhouse, K.D. Adverse events associated with commonly used glaucoma drugs. Int. Ophthalmol. Clin. 39:107-124, 1999. (Pubitemid 29222660)
9. Guenoun, J.M., Baudouin, C., Rat, P., et al. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. 46:4594-4599, 2005. (Pubitemid 44264559)
10. Holló, G. The side effects of the prostaglandin analogues. Expert Opin. Drug Saf. 6:45-52, 2007. (Pubitemid 46150523)
11. Schnober, D., Hofmann, G., Maier, H., et al. Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin. Ophthalmol. 4:1459-1463, 2010.
12. Peplinski, L.S., and Albiani Smith, K. Deepening of lid sul-cus from topical bimatoprost therapy. Optom. Vis. Sci. 81:574-577, 2004. (Pubitemid 39095648)
13. Lee, J.W., Kim, D.Y., and Lee, Y.K. Two cases of deepening of the upper lid sulcus from topical bimatoprost therapy. J. Korean Ophthalmol. Soc. 48:332-336, 2007.
14. Filippopoulos, T., Paula, J.S., Torun, N., et al. Periorbital changes associated with topical bimatoprost. Ophthal. Plast. Reconstr. Surg. 24:302-307, 2008.
15. Tappeiner, C., Perren, B., Iliev, M.E., et al. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost can bimatoprost cause enophthalmos? Klin. Monbl. Augen-heilkd. 225:443-445, 2008. (Pubitemid 352016479)
16. Jayaprakasam, A., and Ghazi-Nouri, S. Periorbital fat atrophy-an unfamiliar side effect of prostaglandin analogues. Orbit 29:357-359, 2010.
17. Yam, J.C., Yuen, N.S., and Chan, C.W. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J. Ocul. Pharmacol. Ther. 25:471-472, 2009.
18. Yang, H.K., Park, K.H., Kim, T.W., and Kim, D.M. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn. J. Ophthalmol. 53:176-179, 2009.
19. Casson, R.J., and Selva, D. Lash ptosis caused by latano-prost. Am. J. Ophthalmol. 139:932-933, 2005.
20. Park, J., Cho, H.K., and Moon, J.I. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn. J. Ophthalmol. 55:22-27, 2011.
21. Yoshida, M., Sagawa, N., Itoh, H., et al. Prostaglandin F (2alpha), cytokines and cyclic mechanical stretch augment matrix metalloproteinase-1 secretion from cultured human uterine cervical fibroblast cells. Mol. Hum. Reprod. 8:681-687, 2002. (Pubitemid 34752930)
22. Hardy, T.G., Joshi, N., and Kelly, M.H. Orbital volume augmentation with autologous micro-fat grafts. Ophthal. Plast. Reconstr. Surg. 23:445-449, 2007. (Pubitemid 350146482)
23. Wolfram-Gabel, R., and Kahn, J.L. Adipose body of the orbit. Clin. Anat. 15:186-192, 2002. (Pubitemid 34454115)
24. Bujalska, I.J., Durrani, O.M., Abbott, J., et al. Characterisation of 11beta-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat. J. Endocrinol. 192:279-288, 2007. (Pubitemid 46444429)
25. Serrero, G., and Lepak, N.M. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem. Biophys. Res. Commun. 233:200-202, 1997. (Pubitemid 27215935)
26. Reginato, M.J., Krakow, S.L., Bailey, S.T., and Lazar, M.A. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 273:1855-1858, 1998. (Pubitemid 28069225)
27. Ajjan, R.A., and Weetman, A.P. New understanding of the role of cytokines in the pathogenesis of Graves' ophthal-mopathy. J. Endocrinol. Investig. 27:237-245, 2004. (Pubitemid 38607476)
28. Fujimori, K., Ueno, T., Nagata, N., et al. Suppression of adipocyte differentiation by aldo-keto reductase 1B3 acting as prostaglandin F2alpha synthase. J. Biol. Chem. 285:8880-8886, 2010.
29. Serrero, G., and Lepak, N. Endocrine and paracrine negative regulators of adipose differentiation. Int. J. Obes. Relat. Metab. Disord. 20:S58-S64, 1996. (Pubitemid 26108583)
30. Sharif, N.A., Kelly, C.R., Crider, J.Y., et al. Ocular hypoten-sive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19:501-515, 2003. (Pubitemid 38030237)
31. Sharif, N.A., Crider, J.Y., Husain, S., et al. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2 + mobilization and MAP kinase activation. J. Ocul. Pharmacol. Ther. 19:437-455, 2003. (Pubitemid 37315132)